Evidence map›Paper›PMID 39781466›Full record

ArticleInternational journal of biological sciences2025

S6K1 is a Targetable Vulnerability in Tumors Exhibiting Plasticity and Therapy Resistance.

Saptadwipa Ganguly, Ravshan Burikhanov, Vitaliy M Sviripa, Sally Ellingson, Jieyun Jiang, Christian M Gosser, David Orren, Eva M Goellner, Gautham G Shenoy, Mahadev Rao and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Saptadwipa GangulyDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Ravshan BurikhanovDepartment of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Vitaliy M SviripaDepartment of Molecular and Cellular Biochemistry and Molecular Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Sally EllingsonDivision of Internal Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Jieyun JiangDepartment of Radiation Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Christian M GosserDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
David OrrenDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Eva M GoellnerDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Gautham G ShenoyDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
Mahadev RaoDepartment of Pharmacy Practice, Center for Translational Research, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
John D'OrazioDepartment of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Christine F BrainsonDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Chang-Guo ZhanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.
Peter H SpielmannDepartment of Molecular and Cellular Biochemistry and Molecular Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
David S WattDepartment of Molecular and Cellular Biochemistry and Molecular Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Vivek M RangnekarDepartment of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Targeting Epigenetic Heterogeneity to Improve Lung Cancer Immunotherapy ResponseR01CA237643 · NCI · UNIVERSITY OF KENTUCKY · PI BRAINSON, CHRISTINE FILLMORE · 2019 to 2023
$1.9M
Suppression of Prostate Tumor Growth and Metastasis by Inhibition of VimentinR01CA187273 · NCI · UNIVERSITY OF KENTUCKY · PI RANGNEKAR, VIVEK M · 2015 to 2019
$1.7M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA187273NCI NIH HHS R01 CA237643
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmRibosomal Protein S6 Kinases, 70-kDaAnimalsAntineoplastic AgentsCell Line, TumorHumansMiceNeoplasmsXenograft Model Antitumor AssaysAntineoplastic Agentsribosomal protein S6 kinase, 70kD, polypeptide 1Ribosomal Protein S6 Kinases, 70-kDaapoptosisebastineplasticityRPS6KB1/S6K1therapy resistance

Identifiers

PMID39781466
PMCPMC11705648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.